Stimulant and other substance use disorders in schizophrenia: Prevalence, correlates and impacts in a population sample

Australian and New Zealand Journal of Psychiatry

Volumn 48, Issue 11, 2014, Pages 1036-1047

  Sara, Grant E ^a,b,c   Burgess, Philip M ^c   Malhi, Gin S ^d   Whiteford, Harvey A ^c   Hall, Wayne C ^c  

^a New South Wales   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Amphetamine; cannabis; cocaine; psychosis; schizophrenia

Indexed keywords

ALCOHOL; AMPHETAMINE; CANNABIS; CENTRAL STIMULANT AGENT; COCAINE; ILLICIT DRUG;

ADULT; ADVERSE OUTCOME; ALCOHOL ABUSE; ARTICLE; AUTOMUTILATION; CANNABIS DISORDER; CANNABIS USE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG DEPENDENCE; EMERGENCY WARD; FEMALE; HOMELESSNESS; HOSPITAL ADMISSION; HOUSING INSTABILITY; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MIGRANT; PREVALENCE; RURAL AREA; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; STIMULANT DISORDER; SUBSTANCE ABUSE; URBAN AREA; ADOLESCENT; AUSTRALIA; DRUG ABUSE; HOSPITALIZATION; MARIJUANA ABUSE; MENTAL HEALTH SERVICE; MIDDLE AGED; PSYCHOLOGY; SELF-INJURIOUS BEHAVIOR; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS; URBAN POPULATION; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; AMPHETAMINE-RELATED DISORDERS; COMORBIDITY; FEMALE; HOSPITALIZATION; HUMANS; MALE; MARIJUANA ABUSE; MENTAL HEALTH SERVICES; MIDDLE AGED; NEW SOUTH WALES; PREVALENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SELF-INJURIOUS BEHAVIOR; SOCIOECONOMIC FACTORS; SUBSTANCE-RELATED DISORDERS; URBAN POPULATION; YOUNG ADULT;

EID: 84910096182     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867414533838     Document Type: Article

References (47)

1. Angrist B, Corwin J, Bartlik B, et al. Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects. Biological Psychiatry. 1987 ; 22: 1357-1368
2. Baeza I, Graell M, Moreno D, et al. Cannabis use in children and adolescents with first episode psychosis: Influence on psychopathology and short-term outcome (CAFEPS study). Schizophrenia Research. 2009 ; 113: 129-137
3. Barr AM, Panenka WJ, MacEwan GW, et al. The need for speed: An update on methamphetamine addiction. Journal of Psychiatry and Neuroscience. 2006 ; 31: 301-313
4. Belsley D. A guide to using the collinearity diagnostics. Computer Science in Economics and Management. 1991 ; 4: 33-50
5. Chouljian TL, Shumway M, Balancio E, et al. Substance use among schizophrenic outpatients: Prevalence, course, and relation to functional status. Annals of Clinical Psychiatry. 1995 ; 7: 19-24
6. Curran C, Byrappa N, McBride A. Stimulant psychosis: A systematic review. British Journal of Psychiatry. 2004 ; 185: 196-204
7. Darke S, Cohen J, Ross J, et al. Transitions between routes of administration among regular amphetamine users. Addiction. 1994 ; 89: 1077-1083
8. Darke S, Kaye S, McKetin R, et al. Major physical and psychological harms of methamphetamine use. Drug and Alcohol Review. 2008 ; 27: 253-262
9. Degenhardt L, Baxter AJ, Lee YY, et al. The global epidemiology and burden of psychostimulant dependence: Findings from the Global Burden of Disease Study 2010. Drug and Alcohol Dependence. 2014 ; 37: 36-47
10. Degenhardt L, Coffey C, Carlin JB, et al. Who are the new amphetamine users? A 10-year prospective study of young Australians. Addiction. 2007a ; 102: 1269-1279
11. Degenhardt L, Roxburgh A, Black E, et al. The epidemiology of methamphetamine use and harm in Australia. Drug and Alcohol Review. 2008 ; 27: 243-252
12. Degenhardt L, Roxburgh A, McKetin R. Hospital separations for cannabis- and methamphetamine-related psychotic episodes in Australia. Medical Journal of Australia. 2007b ; 186: 342-345
13. Gearon JS, Bellack AS. Sex differences in illness presentation, course, and level of functioning in substance-abusing schizophrenia patients. Schizophrenia Research. 2000 ; 43: 65-70
14. González-Pinto A, Alberich S, Barbeito S, et al. Cannabis and first-episode psychosis: Different Long-term outcomes depending on continued or discontinued use. Schizophrenia Bulletin. 2011 ; 37: 631-639
15. Griffith JD, Cavanaugh J, Held J, et al. Dextroamphetamine: Evaluation of psychomimetic properties in man. Archives of General Psychiatry. 1972 ; 26: 97-100
16. Gupta P, Mullin K, Nielssen O, et al. Do former substance users with psychosis differ in their symptoms or function from non-substance users? A systematic meta-analysis. Australian and New Zealand Journal of Psychiatry. 2013 ; 47: 524-537
17. Hall W, Degenhardt L. Cannabis use and psychosis: A review of clinical and epidemiological evidence. Australian and New Zealand Journal of Psychiatry. 2000 ; 34: 26-34
18. Hall W, Degenhardt L. Cannabis and the increased incidence and persistence of psychosis. British Medical Journal. 2011 ; 342: d719
19. Hall W, Hando J, Darke S, et al. Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. Addiction. 1996 ; 91: 81-87
20. Hermens DF, Lubman DI, Ward PB, et al. Amphetamine psychosis: A model for studying the onset and course of psychosis. Medical Journal of Australia. 2009 ; 190: S22-25
21. Keshavan MS, Tandon R, Boutros NN, et al. Schizophrenia, 'just the facts': What we know in 2008: Part 3: Neurobiology. Schizophrenia Research. 2008 ; 106: 89-107
22. Kolliakou A, Sallis H, Joseph C, et al. Reasons for cannabis use in first episode psychosis. Schizophrenia Bulletin. 2013 ; 39: S294
23. Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatrica Scandinavica. 2005 ; 112: 141-148
24. Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: New evidence from brain imaging studies. Journal of Psychopharmacology. 1999 ; 13: 358-371
25. Lieberman J, Kane J, Gadaleta D, et al. Methylphenidate challenge as a predictor of relapse in schizophrenia. American Journal of Psychiatry. 1984 ; 141: 633-638
26. Lieberman JA, Kinon BJ, Loebel AD. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophrenia Bulletin. 1990 ; 16: 97-110
27. McKetin R, Hickey K, Devlin K, et al. The risk of psychotic symptoms associated with recreational methamphetamine use. Drug and Alcohol Review. 2010 ; 29: 358-363
28. Margolese HC, Malchy L, Negrete JC, et al. Drug and alcohol use among patients with schizophrenia and related psychoses: Levels and consequences. Schizophrenia Research. 2004 ; 67: 157-166
29. Martins SS, Gorelick DA. Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population. Drug and Alcohol Dependence. 2011 ; 119: 28-36
30. Miller FT, Tanenbaum JH. Drug abuse in schizophrenia. Hospital and Community Psychiatry. 1989 ; 40: 847-849
31. Modestin J, Studer Gladen CJ, Christen S. A comparative study on schizophrenic patients with dual diagnosis. Journal of Addictive Diseases. 2001 ; 20: 45-55
32. Moore E, Mancuso SG, Slade T, et al. The impact of alcohol and illicit drugs on people with psychosis: The second Australian national survey of psychosis. Australian and New Zealand Journal of Psychiatry. 2012 ; 46: 864-878
33. The International Statistical Classification of Diseases and Related Health Problems, 10th revision, Australian modification (7th edition). Sydney: National Centre for Classification in Health, Faculty of Health Sciences, The University of Sydney ; 2010 :
34. Paparelli A, Di Forti M, Morrison PD, et al. Drug-induced psychosis: How to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Frontiers in Behavioural Neuroscience. 2011 ; 5: 1-9
35. Power BD, Stefanis NC, Dragovic M, et al. Age at initiation of amphetamine use and age at onset of psychosis: The Australian Survey of High Impact Psychosis. Schizophrenia Research. 2014 ; 152: 300-302
36. Ringen PA, Melle I, Berg AO, et al. Cannabis use and premorbid functioning as predictors of poorer neurocognition in schizophrenia spectrum disorder. Schizophrenia Research. 2013 ; 143: 84-89
37. Santos E, Brito L, Cunha M. Cannabis use and the risk of schizophrenia: A systematic literature review. Atencion Primaria. 2013 ; 45: 93
38. Sara G, Burgess P, Harris MG, et al. Stimulant use and stimulant disorders in Australia: Findings from the National Survey of Mental Health and Wellbeing. Medical Journal of Australia. 2011 ; 195: 607-610
39. Sara G, Burgess P, Harris MG, et al. Stimulant disorders: Characteristics and correlates in an Australian population sample. Australian and New Zealand Journal of Psychiatry. 2012 ; 46: 1165-1172
40. Sara G, Burgess P, Malhi G, et al. Differences in associations between cannabis and stimulant disorders in first admission psychosis. Schizophrenia Research. 2013 ; 147: 216-222
41. Sara G, Burgess P, Malhi G, et al. Cannabis and stimulant disorders and readmissions 2 years after first episode psychosis. British Journal of Psychiatry. 2014 ;:
42. Schenker N, Gentleman JF. On judging the significance of differences by examining the overlap between confidence intervals. The American Statistician. 2001 ; 55: 182-186
43. Sorbara F, Liraud F, Assens F, et al. Substance use and the course of early psychosis: A 2-year follow-up of first-admitted subjects. European Psychiatry. 2003 ; 18: 133-136
44. Strakowski SM, DelBello MP, Fleck DE, et al. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Archives of General Psychiatry. 2007 ; 64: 57-64
45. Amphetamines and Ecstasy, 2011 Global ATS Assessment. Vienna: United Nations ; 2011 :
46. Wade D, Harrigan S, Edwards J, et al. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. British Journal of Psychiatry. 2006 ; 189: 229-234
47. Wade D, Harrigan S, McGorry PD, et al. Impact of severity of substance use disorder on symptomatic and functional outcome in young individuals with first-episode psychosis. Journal of Clinical Psychiatry. 2007 ; 68: 767-774